crizotinib PFS. Neither different ALK fusion variants nor the presence of BIM deletion was associated of crizotinib PFS.
Background and Aims: Marie-Bamberger syndrome (MBS), also known as pulmonary hypertrophic osteoarthropathy, is characterized by clubbing of the fingers and toes, symmetrical proliferation of the periosteum at the end of the long tubular bone, and bilateral joint swelling. Many MBS are associated with lung carcinoma as paraneoplastic syndrome.
Methods:
A 65-year-old woman was admitted to our hospital for abnormal chest shadow.
Results: She had noticed a clubbed finger 10 months ago. Bilateral pain occurred in the knees, ankles, and lower leg bones 6 months ago, which symmetrically spread to the left and right anterior chest and back.
Chest computed tomography (CT) showed an anterior mediastinal tumor that diffused into the right thoracic cavity. Pathological findings through percutaneous biopsy of the tumor revealed thymic carcinoma. Although the origin of bilateral pain in the whole body was unknown, the metastatic bone tumor was not diagnosed with CT and X-ray. The pain was then diagnosed as MBS, and chemotherapy with CBDCA + PTX was started. One month later, the primary tumor was reduced, and bilateral pain completely disappeared. The chemotherapy has been continued in the outpatient department. Thymic carcinoma is well controlled, and signs of MBS were not observed.
Conclusion: Approximately 80% of MBS cases are derived from the lungs and 20% occur due to cyanotic heart disease. Most MBS that originated from the lungs are caused by lung cancer. Thymic carcinomas are rare Treatment of the original disease is the best management option for pain. Administration of anti-inflammatory analgesics and radiotherapy for the pain was not effective. It should be noted that MBS symptoms sometimes occur before the discovery of a malignant disease, and not all symptoms occur at once.
We reported a case of thymic carcinoma that took 10 months to diagnose after the occurrence of MBS signs at the first outpatient visit. Methods: in vitro cell line studies using techniques including the histochemistry, western blot, and flow cytometry.
Results: Lipid droplets can be found in the majority of lung cancer cell lines, but their presences are not correlated to the driver mutation types of the cells. These neutral lipids in the lipid droplets could either come from the de novo lipogenesis or extracellular source. Perturbation of the lipid droplet formation inhibits lung cancer cell growth and survival. This result indicates that the neutral lipids stored are important for the lung cancer cell growth and survival.
Conclusion:
The upregulation of lipogenesis in the lung cancer has been known for a long time, but whether lipid droplet can be found in lung cancer is not clear. The current study demonstrates for the first time that the lipid droplets are present in the most molarity of lung cancer cells. Active store neutral lipids within the nutrient sink cancer cells may be a growth advantage selected during tumor evolution and help cancer cell survive during the tumorigenesis. Further studies will be require to answer whether blocking of neutral lipid storage help improve the cancer treatment. Methods: We retrospectively reviewed NSCLC patients treated with ICIs (Nivolumab or Pembrolizumab) at a single center between 2016 January to 2018 March. Tumor burden was defined as the sum of the longest diameter of measurable target lesions evaluated by Response Evaluation Criteria in Solid Tumor ver1.1. We assessed progression-free survival (PFS), overall survival (OS) and adverse event (especially immune-related adverse event (irAE)). The threshold of the sum of tumor diameter for clinical response (CR/PR/SD) was determined using receiver operating characteristic curve analysis. PFS and OS were analyzed by log-rank test using Kaplan-Meier curve after dividing two subgroups according to this threshold.
Results: In total, 53 patients were included in the final analysis.
Median age was 68 years old, 41 (77.4%) were male, 14 were squamous cell carcinoma (SCC) and 39 were non-SCC. 35 patients were treated with Nivolumab, 18 with Pembrolizumab. Disease control rate was 29/53 (54.7%). Low tumor burden group (<80 mm) was associated with a significantly longer OS than high tumor burden group (<80 mm) (not reached
